抗体

乳腺癌1号基因单克隆抗体

MBS190076

0.1毫升

410美元

单克隆

小鼠

未共轭

免疫印迹, 免疫组化, 免疫沉淀

抗体

乳腺癌1号基因单克隆抗体

乳腺癌1号基因

抗乳腺癌1号基因;乳腺癌1号基因

BRCA1; Breast cancer type 1 susceptibility protein; breast cancer type 1 susceptibility protein; OTTHUMP00000212143; OTTHUMP00000212147; OTTHUMP00000212148; OTTHUMP00000212149; OTTHUMP00000212150; OTTHUMP00000212151; OTTHUMP00000212155; RING finger protein 53; BRCA1/BRCA2-containing complex, subunit 1; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein; breast cancer 1, early onset; RING finger protein 53

乳腺癌1号基因;乳腺癌1号基因;IRIS;PSCP;BRCAI;BRCC1;PNCA4;RNF53;BROVCA1;RNF53

BRCA1_HUMAN

单克隆

IgG1 kappa

小鼠

1863

Anti-BRCA1 [Murine MAb recognizes full-length BRCA1 and does not recognize the Dexon 11 splice variant.]. This antibody recognizes full-length BRCA1, a 220 kD nuclear phosphoprotein, and does not recognize the delta exon 11 splice variant. In a high proportion of breast and ovarian cancer cell lines, BRCA1 aberrantly mislocates to the cytoplasm. Its usefulness to monitor functional inactivation of BRCA1 in sporadic breast cancers is under active investigation.

100微克蛋白质G纯化抗体在PBS, pH值7.4

This antibody is stable for at least one (1) year at -70 degree C. Avoid multiple freeze thaw cycles.

免疫印迹 , 免疫组化, 免疫沉淀

Immunoblotting: use at 1-10 ug/ml. Immunoprecipitation: use at 1-10 ug/ml. Immunohistochemistry: use at 1-10 ug/ml. Positive controls: Any normal human tissue, especially those containing rapidly proliferating cells, such as lymphoid germinal centers.

Antigen: GST fusion protein expressed inE. coli corresponding to aa 762-1315 offull-length BRCA1.

Stabilizer: None. Preservatives: None. Available on request. Dilutions Instructions: Dilute in PBS or medium which is identical to that used in the assay system.

Cancer Research Products

Chen, Y et al. (1995) Science 270: 789-791; Chen, C-F et al. (1995) J Biol Chem271: 32863-32868; Chen, Y et al. (1996)Cancer Res 56: 3168-3172.

1698399

AAC37594.1

P38398

207,721 Da

ATF-2 Transcription Factor Network Pathway (138006); ATM Mediated Phosphorylation Of Repair Proteins Pathway (105865); ATM Mediated Response To DNA Double-strand Break Pathway (105864); Androgen Receptor Signaling Pathway (198806); Aurora A Signaling Pathway (137925); BARD1 Signaling Events Pathway (137959); Coregulation Of Androgen Receptor Activity Pathway (138085); DNA Repair Pathway (105837); Double-Strand Break Repair Pathway (105861); E2F Transcription Factor Network Pathway (137934)

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq]

BRCA1: the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACC1 and preventing its dephosphorylation. Defects in BRCA1 are a cause of genetic susceptibility to breast cancer. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association may be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts (via BRCT domains) with CTIP. Associates with RNA polymerase II holoenzyme. Interacts with SMC1 and COBRA1. Interacts (via BRCT domains) with BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with Artemis and claspin. Interacts with H2AFX (phosphorylated on S140). Interacts with CHK1. Interacts with BRCC3. Five human isoforms are produced by alternative splicing and alternative initiation. Isoform 1 and isoform 3 are widely expressed. Isoform 1 is largely nuclear, while isoforms 3 and 5 are cytoplasmic. Protein type: EC 6.3.2.-; Tumor suppressor; Nuclear receptor co-regulator; Transcription, coactivator/corepressor; Ubiquitin ligase; Ubiquitin conjugating system. Chromosomal Location of Human Ortholog: 17q21. Cellular Component: nucleoplasm; gamma-tubulin ring complex; condensed nuclear chromosome; protein complex; BRCA1-BARD1 complex; cytoplasm; plasma membrane; chromosome; ribonucleoprotein complex; nucleus; ubiquitin ligase complex. Molecular Function: tubulin binding; protein binding; enzyme binding; androgen receptor binding; DNA binding; zinc ion binding; RNA binding; ubiquitin protein ligase binding; transcription coactivator activity; ubiquitin-protein ligase activity; damaged DNA binding; ligase activity. Biological Process: genetic imprinting; apoptosis; positive regulation of transcription, DNA-dependent; dosage compensation, by inactivation of X chromosome; centrosome cycle; protein ubiquitination; negative regulation of histone H3-K4 methylation; positive regulation of histone H3-K4 methylation; chromosome segregation; negative regulation of histone acetylation; regulation of apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; double-strand break repair; DNA replication; fatty acid biosynthetic process; negative regulation of fatty acid biosynthetic process; positive regulation of histone H3-K9 methylation; negative regulation of histone H3-K9 methylation; protein autoubiquitination; positive regulation of DNA repair; chordate embryonic development; postreplication repair; DNA repair; negative regulation of centriole replication; double-strand break repair via homologous recombination; regulation of cell proliferation; regulation of transcription from RNA polymerase II promoter; positive regulation of angiogenesis; DNA damage response, signal transduction resulting in induction of apoptosis; regulation of transcription from RNA polymerase III promoter; positive regulation of protein ubiquitination; response to estrogen stimulus; androgen receptor signaling pathway; positive regulation of transcription from RNA polymerase II promoter; positive regulation of histone acetylation; response to ionizing radiation; negative regulation of transcription, DNA-dependent; G2/M transition DNA damage checkpoint; response to DNA damage stimulus. Disease: Breast-ovarian Cancer, Familial, Susceptibility To, 1; Pancreatic Cancer, Susceptibility To, 4; Breast Cancer

0.1毫升

410美元